Pharma says EU GDP proposals expensive, supply-chain nightmare

In July, the EU published draft guidelines it said would help prevent falsified drugs from getting into the approved supply chain. Now the pharmaceutical industry is having its say, and it is generally outraged. 

If implemented, logistics and pharmaceutical companies say the rules would dramatically increase supply-chain costs while being virtually impossible to comply with, reports Outsourcing-Pharma.com.

Criticisms were particularly sharp for this proposal.

"Where transportation hubs are utilized in the supply chain, a maximum time limit of normally 24 hours should be set to await the next stage of the transportation route. Where medicinal products are held on the premises for longer than this defined time limit, the hub will be deemed to be acting as a storage site and required to obtain a wholesale distribution authorization. For refrigerated product any storage at a transportation hub for any period of time would require that premises to hold a wholesalers distribution authorization."

Also, products are often at a site for longer--for example, over weekends and holidays--critics point out. In some geographies, trucks are banned on those days.

"These requirements would significantly increase the cost of the medicinal product supply chains," shipper UPS wrote in its response to the EC, according to Outsourcing-Pharma.com.

- check out the story from Outsourcing-Pharma.com
- read the EU draft GDP rules (.pdf)
- and get the responses

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.